Market news

AtriCure has delivered a strong run over the past year, and the latest close at US$60.77 puts a clear spotlight on what investors are paying for its sales. The question now is how that recent performance lines up with the revenue the business is actually generating. The share price has gained 73.5% over the past year, which puts added weight on whether the current valuation can be explained by its sales base. The company’s focus on cardiac surgical devices means future growth in procedure...

AtriCure (ATRC) has drawn fresh attention after its shares closed at US$60.77, with recent returns over the past month and past 3 months sharply outpacing many healthcare peers. Recent trading has been strong for AtriCure, with a 30-day share price return of 24.84% and a 90-day share price return of 101.36%. This feeds into a year-to-date share price gain of 54.75% and a 1-year total shareholder return of 73.48%, even though the 5-year total shareholder return is down 12.62%. Spot fresh...

Salvatore Privitera, Chief Technical Officer, on September 23, 2026, sold 4,519 shares in Atricure (

Privitera executed the sale under a pre-established Rule 10b5-1 trading plan.

Detailed price information for Atricure Inc (ATRC-Q) from The Globe and Mail including charting and trades.

AtriCure (ATRC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Privitera Salvatore, Chief Technical Officer, on September 02, 2026, sold 7,763 shares in Atricure (

AtriCure (ATRC) has an average rating of buy and mean price target of $51.67, according to analysts

Here is how AtriCure (ATRC) and Aveanna Healthcare (AVAH) have performed compared to their sector so far this year.

Opportunities center on pulsed field ablation, advanced mapping catheters and LAAC implants, driven by aging populations and demand for safer, drug-free care. Asia-Pacific expansion, ambulatory procedures, improving reimbursement and regulatory support offer further growth. Atrial Fibrillation Treatment Devices Market Atrial Fibrillation Treatment Devices Market Dublin, Aug. 26, 2026 (GLOBE NEWSWIRE) -- The "Atrial Fibrillation Treatment Devices Market by Type of Device, Type of Technology, End

MASON, Ohio, August 25, 2026--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming 2026 Wells Fargo Health Care Conference.

AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product adoption, expanding procedure volumes and progress in clinical trials. Speaking at the Canaccord Genuity G

The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.

Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.

It was reported on August 7, that Maggie Yuen, Director at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with the U.S. Securities and

It was reported on July 30, that Vinayak Doraiswamy, Chief Scientific Officer at AtriCure (NASDAQ:ATRC) executed a significant insider sell, according to an SEC filing. What Happened: According to a Form 4 filing with

A significant insider transaction involving the exercise of company stock options was reported on July 30, by Sven Wehrwein, Board Member at AtriCure (NASDAQ:ATRC), as per the latest SEC filing. What Happened: A Form 4

Sven Wehrwein, Director, on July 28, 2026, sold 25,000 shares in Atricure (ATRC) for $946,000. Follo

AtriCure (ATRC) drew fresh investor attention after filing two shelf registrations related to employee stock ownership offerings, covering up to 2,250,000 common shares and approximately US$78.8 million in potential issuance capacity. See our latest analysis for AtriCure. AtriCure’s recent shelf registrations arrive after a sharp swing in sentiment, with the stock posting a 42.47% 30 day share price return and a 16.40% 1 year total shareholder return, despite a weaker 3 year and 5 year total...

Investors need to pay close attention to ATRC stock based on the movements in the options market lately.

Tipranks Press Release.

AtriCure, Inc. (NASDAQ:ATRC) has been delivering revenue growth and improved profitability, but the bigger question for investors is whether the latest results had any underlying catalysts strong enough to support the long-term growth potential. The company reported its Q2 FY26 earnings on July 23, delivering revenue of $153.6 million and an adjusted EPS of $0.18. […]

MASON, Ohio, July 27, 2026--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in two upcoming investor conferences.

Tipranks Press Release.

Tipranks Press Release.

Detailed price information for Prime Medicine Inc (PRME-Q) from The Globe and Mail including charting and trades.